ZIMMER BIOMET HOLDINGS, INC. Net Change in Cash
ZIMMER BIOMET HOLDINGS, INC. (ZBH) reported Net Change in Cash of -$181.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-05
- ZIMMER BIOMET HOLDINGS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$167.70M, a 119.52% decline year-over-year.
- ZIMMER BIOMET HOLDINGS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was $859.10M.
- ZIMMER BIOMET HOLDINGS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$22.70M.
- ZIMMER BIOMET HOLDINGS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$45.50M.
- ZIMMER BIOMET HOLDINGS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $66.40M, a 39.47% decline from fiscal 2024.
- ZIMMER BIOMET HOLDINGS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $109.70M, a 173.57% increase from fiscal 2023.
- ZIMMER BIOMET HOLDINGS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $40.10M.
- ZIMMER BIOMET HOLDINGS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$102.80M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$181.90M 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | -$167.70M 10-Q · filed 2026-05-01 | |||
| 2025-12-31 | $66.40M 10-K · filed 2026-02-20 | |||
| 2025-09-30 | $767.20M 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $31.40M 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | $859.10M 10-Q · filed 2026-05-01 | |||
| 2024-12-31 | $109.70M 10-K · filed 2026-02-20 | |||
| 2024-09-30 | $153.30M 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | $4.40M 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | -$22.70M 10-Q · filed 2025-05-05 | |||
| 2023-12-31 | $40.10M 10-K · filed 2026-02-20 | |||
| 2023-09-30 | -$83.50M 10-Q · filed 2024-10-30 | |||
| 2023-06-30 | -$55.90M 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | -$45.50M 10-Q · filed 2024-05-02 | |||
| 2022-12-31 | -$102.80M 10-K · filed 2025-02-25 | |||
| 2022-09-30 | $66.90M 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | -$92.10M 10-Q · filed 2023-08-01 | |||
| 2022-03-31 | -$42.70M 10-Q · filed 2023-05-02 | |||
| 2021-12-31 | -$323.60M 8-K · filed 2024-08-07 | |||
| 2021-09-30 | $117.50M 10-Q · filed 2022-11-02 | |||
| 2021-06-30 | $240.30M 10-Q · filed 2022-08-02 | |||
| 2021-03-31 | -$77.80M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $184.20M 10-K · filed 2023-02-24 | |||
| 2020-09-30 | $349.40M 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | $95.50M 10-Q · filed 2021-08-03 | |||
| 2020-03-31 | $1.82B 10-Q · filed 2021-05-04 | |||
| 2019-12-31 | $75.10M 8-K · filed 2022-06-22 | |||
| 2019-09-30 | -$30.30M 10-Q · filed 2020-11-06 | |||
| 2019-06-30 | -$139.70M 10-Q · filed 2020-08-05 | |||
| 2019-03-31 | $44.00M 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | $18.40M 10-K · filed 2021-02-22 | |||
| 2018-09-30 | $200.00K 10-Q · filed 2019-11-05 | |||
| 2018-06-30 | -$43.20M 10-Q · filed 2019-08-05 | |||
| 2018-03-31 | $1.24B 10-Q · filed 2019-05-06 | |||
| 2017-12-31 | -$109.70M 10-K · filed 2020-02-21 | |||
| 2017-09-30 | -$153.30M 10-Q · filed 2018-11-01 | |||
| 2017-06-30 | -$184.10M 10-Q · filed 2018-08-06 | |||
| 2016-12-31 | -$825.20M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STERIS plc (STE) | Ireland | $20.343B | 25.49 |
| ALIGN TECHNOLOGY INC (ALGN) | United States | $10.346B | 29.06 |
| MSA Safety Inc (MSA) | United States | $7.023B | 21.47 |
| ESTABLISHMENT LABS HOLDINGS INC. (ESTA) | $1.954B | -65.76 | |
| Cadre Holdings, Inc. (CDRE) | United States | $1.123B | 33.88 |
| Enovis CORP (ENOV) | United States | $1.053B | -1.18 |
| Anteris Technologies Global Corp. (AVR) | United States | $0.746B | |
| Sanara MedTech Inc. (SMTI) | United States | $0.323B | -6.81 |
| Inogen Inc (INGN) | United States | $0.139B | -7.00 |
| Conexeu Sciences Inc. (CNXU) | United States | $0.111B |